Aztiq and Innobic completed the acquisition of Alvogen for $500m.

Aztiq, a healthcare investor, and Innobic, a life sciences company, completed the acquisition of Alvogen, a pharmaceutical company, from CVC Capital Partners and Temasek for $500m. "I would like to take this opportunity to thank the existing shareholders for their great support in the transformation of both Lotus and Adalvo, and at the same time to welcome our new partner Innobic as we look forward to carrying out the essential work of expanding access to medicines to more people who need them. With our vast collective expertise, and the comprehensive geographic networks and solid market intelligence in ASEAN brought by innobic and PTT, I believe that Lotus and Adalvo will have a compelling competitive advantage, enabling both enterprises to support one another and advance their global leadership in their sectors," Robert Wessman, Alvogen Chairman and CEO.